GLP-1 Vision Loss (NAION) Lawsuit 2026: Semaglutide Eye Claims

GLP-1 receptor agonist drugs, including Ozempic, Wegovy, Saxenda, and Trulicity, are the subject of product liability claims alleging they caused a serious eye condition called NAION, a sudden and usually permanent loss of vision. These claims are centralized in a federal multidistrict litigation that is separate from the better known stomach injury cases, and the underlying science is recent and still being studied. This page explains the claims, the science, and the current status neutrally. It is general information and attorney advertising, not legal advice, and not a statement that anyone has a claim.

This page is part of our Mass Tort & Product Liability overview, and it concerns a different injury from our Ozempic and GLP-1 stomach injury guide.

What NAION is and the alleged harm

Non-arteritic anterior ischemic optic neuropathy, or NAION, is a condition in which blood flow to the front of the optic nerve is interrupted, causing sudden vision loss in one eye that is usually painless and often permanent. There is no proven treatment that reverses it, and a minority of patients later experience the second eye becoming involved. NAION is the most common sudden optic nerve disorder in adults over 50, and it has its own independent risk factors, including diabetes, high blood pressure, sleep apnea, and a particular optic nerve shape sometimes called a crowded disc. The lawsuits allege that these drugs increase the risk of NAION and that the manufacturers did not adequately warn patients and prescribers. These are descriptions of the allegations, not a finding that semaglutide caused any individual person's vision loss.

Note: These are allegations being tested in court. NAION has several recognized causes unrelated to any medication, and a defendant can be expected to argue that another factor explains a given case. A lawsuit reflects what a plaintiff claims, not a final determination of liability.

What the science and regulators say

The evidence linking semaglutide to NAION is recent and not uniform. In July 2024, researchers at Mass Eye and Ear, a Harvard affiliated hospital, published a study in JAMA Ophthalmology reporting that patients prescribed semaglutide had a higher rate of NAION than comparable patients, with a hazard ratio of about 4 among people with type 2 diabetes and higher among people who were overweight or obese. The authors were explicit that the study suggested an association and that further research was needed to assess causation. Later and larger population studies found a real but smaller association: a 2025 Danish and Norwegian registry study reported roughly a threefold relative increase, and a large Danish cohort found that semaglutide roughly doubled the five year risk, while both stressed that the absolute risk remains low.

Regulators have described the risk as very rare. In 2025, the European Medicines Agency concluded that NAION is a very rare side effect of semaglutide, occurring in up to about 1 in 10,000 users, and recommended adding it to product information, and the World Health Organization issued an alert to clinicians. In February 2026, the UK medicines regulator advised that semaglutide may very rarely be associated with NAION and that product information would be updated. As of mid 2026, the U.S. Food and Drug Administration had not added a NAION warning to the U.S. prescribing information for these drugs. The presence, or absence, of a warning reflects a regulator's assessment of reports and studies, not proof that the drug caused any particular case.

Note: Nothing here establishes that semaglutide causes NAION or that it caused any individual's vision loss. The studies disagree on the size of the risk, the absolute risk appears low, and the science continues to evolve.

A separate litigation from the GLP-1 stomach injury cases

It is important not to confuse this litigation with the larger GLP-1 stomach injury cases. The vision claims are handled in MDL No. 3163, while the gastrointestinal claims, which allege injuries such as gastroparesis and intestinal obstruction, are handled in MDL No. 3094. Both are centralized in the Eastern District of Pennsylvania before Judge Karen S. Marston, but they are separate proceedings with separate dockets, different injuries, different medical experts, and different proof of causation. The panel declined a suggestion from Eli Lilly that the eye claims be folded into MDL No. 3094. It created a separate NAION MDL so that Judge Marston could determine the appropriate level of coordination between the two litigations, make tracking of cases easier, and facilitate orderly docketing in each, and because it had handled a second injury arising from the same drug the same way in the Taxotere eye injury litigation. The panel expected substantial overlap between pretrial proceedings in the two MDLs, which involve the same defendants and largely the same counsel. Our companion guide covers the stomach injury litigation in detail.

The status of the NAION litigation (as of September 2026)

The Judicial Panel on Multidistrict Litigation created MDL No. 3163, formally titled In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Products Liability Litigation, by a transfer order entered on December 15, 2025, consolidating an initial group of 21 actions from three districts in the Eastern District of Pennsylvania before Judge Karen S. Marston. As of the Judicial Panel's September 1, 2026 report the MDL had 216 actions pending, still far smaller than the gastrointestinal litigation, and it has moved out of initial coordination into active pretrial work. The court set a Science Day for June 2, 2026, and in Case Management Order No. 12, entered July 2, 2026, it granted early discovery and motion practice on the cross-cutting issues of general causation and preemption or warning adequacy, recording a timetable with fact discovery to be complete in October 2026, expert discovery by the end of 2026, and motions fully briefed in the first quarter of 2027. There have been no bellwether trials, no verdicts, and no settlement, and the central question of whether the science supports a causal link has not been decided. Litigation status can change quickly, so the current posture should be confirmed before relying on any figure.

Who may be involved

The people generally involved in this litigation are individuals who were prescribed and took one of the GLP-1 drugs named in the litigation, such as Ozempic, Wegovy, Saxenda, or Trulicity, and were later diagnosed with NAION or sudden, unexplained vision loss in one eye. Whether any particular person may have a claim depends on the specific facts, including which drug was used and for how long, the timing and diagnosis of the vision loss, the medical records, and the law of the relevant state. Because NAION has several independent causes, a key question in any case is whether the evidence connects the vision loss to the drug rather than to another risk factor. Use of one of these drugs alone does not establish a claim, and nothing here suggests that every patient has a claim or that any outcome is assured.

Deadlines and why they matter

Claims like these are subject to statutes of limitations, which are legal deadlines to file suit. These deadlines vary by state and by the type of claim, and many states measure the deadline from when a person knew or reasonably should have known that an injury may be linked to a product, a concept sometimes called the discovery rule. Because the studies and regulatory actions described above are recent, the question of when a person reasonably should have made that connection can be contested. There is no single national deadline, and this page does not state any individual's deadline. Missing a deadline can permanently bar a claim, so people who believe they may be affected often act promptly, and a licensed attorney in the relevant state can determine which deadline applies.

How to evaluate your options

If you are trying to understand your legal options, the appropriate step is to speak with a licensed attorney who handles this type of case. An attorney can assess the facts, explain the law in your state, and advise whether you may have a claim, which this page cannot do. It helps to gather any records you have, such as proof of which GLP-1 drug you used and when, your prescription and pharmacy history, and the ophthalmology records confirming an NAION diagnosis and its date. Most mass tort and personal injury attorneys offer a free, confidential consultation, and many work on a contingency basis, meaning a fee is generally owed only if there is a recovery. A consultation creates no obligation.

Frequently Asked Questions

What is the GLP-1 or Ozempic vision loss lawsuit about?

It involves claims that GLP-1 receptor agonist drugs, which the transfer order identifies as Ozempic, Wegovy, Saxenda, and Trulicity, caused a sudden eye injury called NAION (non-arteritic anterior ischemic optic neuropathy), and that Novo Nordisk and Eli Lilly failed to warn adequately. The panel described plaintiffs as bringing substantially identical claims for failure to warn, design defect, and breach of warranties under state law.

Is this the same as the Ozempic stomach lawsuit?

No. The vision claims are in MDL No. 3163, and the gastrointestinal claims, such as gastroparesis, are in a separate proceeding, MDL No. 3094. Both are before the same judge in the Eastern District of Pennsylvania, but they are different cases with different injuries and different science.

Does semaglutide cause NAION?

This is not settled. A 2024 study reported an association, and European and UK regulators have listed NAION as a very rare side effect, but the authors said their study does not prove causation, later studies found a smaller risk, and the U.S. FDA had not added a NAION warning as of mid 2026. A lawsuit is not proof of causation in any individual case.

What is the case number and where is it?

The cases are consolidated in In re: GLP-1 RAs Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Products Liability Litigation, MDL No. 3163, in the U.S. District Court for the Eastern District of Pennsylvania before Judge Karen S. Marston. The MDL was created in December 2025.

Is there a settlement?

As of September 2026 there is no settlement and no bellwether trial in the NAION litigation. It is a relatively small docket, with 216 actions pending as of the Judicial Panel's September 1, 2026 report, and key questions about the science have not been decided. Be cautious of any source that promises a settlement or a dollar amount.

Who qualifies to file a claim?

There is no automatic qualification. Whether a person may have a claim depends on the facts, including which drug was used and for how long, the NAION diagnosis and its timing, the medical records, and the law of the relevant state. A licensed attorney can evaluate eligibility.

Is there a deadline to file?

Yes, but it varies. Statutes of limitations differ by state and by claim type, and many states measure the deadline from when a person reasonably should have connected the injury to the drug. There is no single national deadline, so the applicable one should be confirmed with an attorney in the relevant state.